Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dey, a subsidiary of Mylan, is all set to market and distribute Emsam in the US. FDA approved EMSAM, a selegiline transdermal system, is a monoamine oxidase inhibitor for the treatment of major depressive disorder.
Subscribe to our email newsletter
Emsam was previously marketed and distributed by Bristol-Myers Squibb through a commercialization agreement. The transfer of distribution, marketing and sales to Dey concludes the three-year agreement with Bristol-Myers.
Carolyn Myers, President, Dey, said: I am very pleased that we have the opportunity to bring the marketing and distribution of Emsam back into the Mylan family of companies. Emsam was developed by Somerset in collaboration with Mylan and is manufactured by MTI. Now, we can market and distribute this important product through our specialty division, Dey, and the entire supply and distribution process will benefit from additional efficiencies and cost synergies going forward.